艾迪注射液联合立体定向放射治疗原发性肝癌疗效观察

目的评价艾迪注射液联合X-刀立体定向放射治疗（SRT）对原发性肝癌（PHC）的疗效。方法107例原发性肝癌患者行SRT治疗，SRT分次量3～4Gy，3次／周，治疗剂量40-60Gy。57例联合艾迪注射液治疗（艾迪注射液60ml＋0．9％氯化钠溶液或5％葡萄糖溶液500ml静脉滴注，第1～21天，间隔10d后行第2个疗程治疗）。结果艾迪联合组与SRT组总有效率、疾病控制率及1、2、3a生存率分别为：75．5％94．7％与72％、92％及65％、29．8％、10．5％与56％、22％、8％，两组在总有效率、疾病控制率、生存率等方面差异无统计学意义（P〉0．05）；骨髓抑制发生率及生活质量方面艾迪联合组与SRT组分别为22．8％与42％及73．7％与52％，差异有统计学意义（P〈0．05）。结论艾迪注射液与SRT联合治疗原发性肝癌具有明显抗辐射、提高肝癌患者生活质量作用，值得进一步研究。

The analysis of therapeutic effect of primary liver cancer treated by Aidi injection combined with stereotactic radiotherapy

Objective To analyze the therapeutic effect of primary liver cancer treated by Aidi injection combined with stereotactie radiotherapy SRT. Methods 50 patients with primary liver cancer were treated with X-ray SRT, and 57 patients were treated with Aidi injection combined with SRT, SRT：DT 40- 60 Gy（ 300 - 400 cGy/F, 3F/w, Aidi in- jection 60ml＋ NS/5%GS 500ml,dl-d14,the second course line spacing 10 days. Results All patients were examined with image of CT or MRI . The total effective rate（CR＋PR）,the disease control rate （DCR） and 1.2,3 years survival rates was 75. 5%,94. 7% vs 72%,92% and 65%,29.8%,10.5% VS 56%,22%,8%,There were no differences in curative effect and survival rates（P〉0.05）. Bone marrow restrain incidence and life for the total effective rate was ignificantlys sever in Aidi group than in SRT group （ 22.8%vs42% and 73.7% vs 52%） （P〈 0. 05 ）. Conclusions Aidi injection combined with SRT in the treatment of primary liver cancer can resist radiation and improve patients quality of life.